Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.38 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.35 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1205074 | 0.95 | ALDH1A1 (0.42) | KMT2AMEN1ALDH1A1CREBBPEP300 | |
| SCHEMBL1204141 | 0.90 | MEN1 (0.45) | KMT2AMEN1ALDH1A1CREBBPEP300 | |
| SCHEMBL1188534 | 0.86 | KMT2A (0.53) | KMT2AMEN1ALDH1A1CREBBPGAA | |
| SCHEMBL1204024 | 0.85 | CREBBP (0.43) | KMT2AMEN1ALDH1A1CREBBPEP300 | |
| SCHEMBL18095278 | 0.81 | KMT2A (0.57) | KMT2AMEN1ALDH1A1CREBBPNPSR1 | |
| SCHEMBL18105999 | 0.78 | LMNA (0.44) | KMT2AMEN1ALDH1A1CREBBPEP300 | |
| SCHEMBL19889483 | 0.78 | LMNA (0.44) | KMT2AMEN1ALDH1A1CREBBPEP300 | |
| SCHEMBL19889482 | 0.77 | KMT2A (0.48) | KMT2AMEN1ALDH1A1CREBBPGAA | |
| SCHEMBL18105997 | 0.77 | KMT2A (0.48) | KMT2AMEN1ALDH1A1CREBBPGAA | |
| SCHEMBL4315290 | 0.76 | CREBBP (0.58) | KMT2AMEN1ALDH1A1CREBBPEP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9079906-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI (FR) | 2015-07-14 | — | — | US | disclosed |
| US-20120010203-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2012-01-12 | — | — | US | disclosed |
| US-8076336-B2 | Triazolopyridazines as PAR1 inhibitors, production thereof, and use as medicaments | SANOFI-AVENTIS (FR) | 2011-12-13 | — | — | US | disclosed |
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | SANOFI-AVENTIS (FR) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034451-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | KMT2A 2751/4885MEN1 1179/4885ALDH1A1 1015/4885 |
| US-20120010203-A1 | TRIAZOLOPYRIDAZINES AS PAR1 INHIBITORS, PRODUCTION THEREOF, AND USE AS MEDICAMENTS | F2R, F2RL3, F2RL1 | KMT2A 2751/4885MEN1 1179/4885ALDH1A1 1015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.